End-of-day quote
Hong Kong S.E.
06:00:00 2024-05-26 pm EDT
|
5-day change
|
1st Jan Change
|
9.59
CNY
|
+0.31%
|
|
+0.42%
|
-19.95%
|
Fiscal Period: December |
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
9,048
|
4,349
|
3,554
|
-
|
-
|
Enterprise Value (EV)
1 |
8,836
|
4,475
|
3,687
|
3,490
|
3,148
|
P/E ratio
|
-14.3
x
|
-11.3
x
|
-40.4
x
|
37.1
x
|
19.3
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
16.9
x
|
6.07
x
|
3.87
x
|
3.1
x
|
2.57
x
|
EV / Revenue
|
16.6
x
|
6.24
x
|
4.01
x
|
3.05
x
|
2.28
x
|
EV / EBITDA
|
-19.8
x
|
-33.1
x
|
44.4
x
|
13.8
x
|
6.92
x
|
EV / FCF
|
-16,257,344
x
|
-
|
-
|
-
|
-
|
FCF Yield
|
-0%
|
-
|
-
|
-
|
-
|
Price to Book
|
7.89
x
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
399,398
|
399,398
|
399,398
|
-
|
-
|
Reference price
2 |
22.65
|
10.89
|
8.898
|
8.898
|
8.898
|
Announcement Date
|
3/27/23
|
3/27/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
354.6
|
533.9
|
716.9
|
919.3
|
1,145
|
1,383
|
EBITDA
1 |
-
|
-447
|
-135.1
|
83.06
|
252.4
|
454.8
|
EBIT
1 |
-
|
-621.1
|
-317.4
|
-98.43
|
94.9
|
250.7
|
Operating Margin
|
-
|
-116.33%
|
-44.28%
|
-10.71%
|
8.29%
|
18.14%
|
Earnings before Tax (EBT)
1 |
-
|
-601.4
|
-380.2
|
-89
|
115
|
214
|
Net income
1 |
-545.6
|
-601.9
|
-383
|
-89
|
98
|
182
|
Net margin
|
-153.88%
|
-112.75%
|
-53.42%
|
-9.68%
|
8.56%
|
13.16%
|
EPS
2 |
-
|
-1.580
|
-0.9600
|
-0.2200
|
0.2400
|
0.4600
|
Free Cash Flow
|
-
|
-543.5
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-101.81%
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
8/19/22
|
3/27/23
|
3/27/24
|
-
|
-
|
-
|
Fiscal Period: December |
2022 S2
|
2023 S1
|
2023 S2
|
2024 S1
|
2024 S2
|
---|
Net sales
1 |
304.8
|
326.8
|
390.1
|
396.5
|
527
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
EBIT
|
-328.4
|
-
|
-157.8
|
-
|
-
|
Operating Margin
|
-107.75%
|
-
|
-40.45%
|
-
|
-
|
Earnings before Tax (EBT)
|
-
|
-
|
-
|
-
|
-
|
Net income
|
-
|
-
|
-
|
-
|
-
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
EPS
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/27/23
|
9/26/23
|
3/27/24
|
-
|
-
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
126
|
133
|
-
|
-
|
Net Cash position
1 |
-
|
211
|
-
|
-
|
64.3
|
406
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-0.9358
x
|
1.606
x
|
-
|
-
|
Free Cash Flow
|
-
|
-544
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-50.3%
|
-
|
-12.7%
|
12.3%
|
18.6%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
2.870
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-0.8000
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
240
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
45%
|
-
|
-
|
-
|
-
|
Announcement Date
|
8/19/22
|
3/27/23
|
3/27/24
|
-
|
-
|
-
|
Last Close Price
8.898
CNY Average target price
14.21
CNY Spread / Average Target +59.75% Consensus |
1st Jan change
|
Capi.
|
---|
| -19.95% | 489M | | +67.53% | 63.85B | | -0.77% | 41.83B | | +44.98% | 40.65B | | -10.87% | 27.12B | | +13.30% | 26.52B | | -22.79% | 18.69B | | +4.70% | 12.73B | | +24.10% | 12.11B | | +27.41% | 12.07B |
Other Biotechnology & Medical Research
|